RNA Aptamers Neutralizing Extracellular Histones
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS) are ineffective in preventing the development of these conditions, leading to significant morbidity and mortality, with existing therapies focusing on supportive care rather than direct prevention or reversal.
Innovation Solution
Development of RNA aptamers specifically targeting extracellular histones to interrupt the self-propagating cycle of tissue injury, using chemically modified RNA molecules that bind with high affinity to histones H3 and H4, thereby neutralizing their toxic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If supportive care is provided to MODS/ARDS patients, then patient survival is maintained through organ support, but there is no direct prevention or reversal of the disease process
Solution Approach 1:
The patent introduces RNA aptamers as intermediary molecules that specifically bind to extracellular histones, preventing them from mediating tissue injury. The aptamers act as mediators between the harmful histones and the body's natural defenses, neutralizing the toxic effects without requiring direct intervention in the complex inflammatory cascade.
Solution Approach 2:
The invention extracts and neutralizes the specific harmful component (extracellular histones) from the disease process. By using aptamers that selectively bind to histones H3 and H4, the treatment removes the toxic effect of histones from the system while leaving other physiological processes intact.
2Ease of manufacture
If no specific pharmacotherapy is used for ALI/ARDS, then current mechanical ventilation and organ support strategies can be maintained, but mortality remains high at approximately 40%
Solution Approach 1:
The patent changes the therapeutic parameter from supportive care alone to targeted molecular intervention. By introducing aptamers with specific binding affinity for histones, the treatment transforms the approach from general organ support to precise molecular therapy, thereby improving patient outcomes without complicating the overall treatment protocol.
3Object-generated harmful factors
If extracellular histones are not targeted, then the self-propagating cycle of tissue injury continues, but no effective therapy exists to interrupt this cycle
Solution Approach 1:
The patent applies preliminary anti-action by administering aptamers that preemptively bind to extracellular histones before they can propagate tissue injury. This prevents the self-propagating cycle from establishing or continues it, thereby preventing further damage accumulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA aptamers effectively terminate the cycle of histone-mediated tissue injury, reducing morbidity and mortality in high-risk patients by selectively binding and neutralizing circulating histones, thus preventing the progression of MODS and ARDS.
Implementation Method 1
the aptamer specifically targets both H3 and/or H4... the RNA aptamers effectively terminate the cycle of histone-mediated tissue injury by selectively binding and neutralizing circulating histones
Data Source
AI summary
The present invention relates to optimized aptamers and methods of using these aptamers.